Skip to main content

Advertisement

SpringerLink
Log in

Warranty periods for normal myocardial perfusion stress SPECT

  • Original Article
  • Published:
Journal of Nuclear Cardiology Aims and scope

Abstract

Background

To assess different warranty periods following a normal myocardial perfusion SPECT based on patients’ clinical characteristics and the type of stress performed.

Methods and Results

A study was done of 2,922 consecutive patients (62.9 ± 13 years; 53.4% women) with a normal stress-rest SPECT. The warranty period was defined as the period during which patients remained at a low risk (<1% events/year) of total mortality (TM), or hard events (HE) (cardiac death or non-fatal myocardial infarction). Of these patients, 2,051 were given an exercise myocardial perfusion imaging (Ex-MPI); 461 submaximal exercise plus dipyridamole (Ex+Dipy-MPI); and 410 dipyridamole (Dipy-MPI). During a mean follow-up of 5 ± 3.3 years, a significant reduction (P < .05) of the warranty period for TM (13.5, 9.6 and 8 months) and HE (34.8, 20.5 and 8.2 months) was observed, for Ex-MPI, Ex+Dipy-MPI and Dipy-MPI, respectively. Other warranty period determinants were the clinical variables of age, sex, diabetes and known coronary artery disease. An abnormal left ventricular ejection fraction on gated-SPECT also significantly shortened the warranty period for HE in patients undergoing Ex+Dipy-MPI (P = .001) or Dipy-MPI alone (P = .007).

Conclusions

The warranty period for a normal stress-rest SPECT is highly variable since it is primarily determined by the type of stress, the patient’s clinical characteristics and LVEF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004;11:171-85.

    Article  PubMed  Google Scholar 

  2. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, et al. Myoview multicenter registry. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: Results from the multicenter registry of 4,728 patients. J Nucl Med 2003;44:134-9. Erratum in: J Nucl Med 2003;44:648.

  3. Hachamovitch R, Hayes S, Friedman JD, Cohen I, Shaw LJ, Germano G, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: What is the warranty period of a normal scan? J Am Coll Cardiol 2003;41:1329-40.

    Article  PubMed  Google Scholar 

  4. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002;105:32-40.

    Article  PubMed  Google Scholar 

  5. Abbott BG, Afshar M, Berger AK, Wackers FJ. Prognostic significance of ischemic electrocardiographic changes during adenosine infusion in patients with normal myocardial perfusion imaging. J Nucl Cardiol 2003;10:9-16.

    Article  PubMed  Google Scholar 

  6. Klodas E, Miller TD, Christian TF, Hodge DO, Gibbons RJ. Prognostic significance of ischemic electrocardiographic changes during vasodilator stress testing in patients with normal SPECT images. J Nucl Cardiol 2003;10:4-8.

    Article  PubMed  Google Scholar 

  7. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99 m sestamibi SPECT study. J Nucl Cardiol 2003;10:261-6.

    Article  PubMed  Google Scholar 

  8. Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: A meta-analysis. J Nucl Cardiol 2004;11:551-61.

    Article  PubMed  Google Scholar 

  9. Schinkel AF, Elhendy A, Bax JJ, van Domburg RT, Huurman A, Valkema R, et al. Prognostic implications of a normal stress technetium-99 m-tetrofosmin myocardial perfusion study in patients with a healed myocardial infarct and/or previous coronary revascularization. Am J Cardiol 2006;97:1-6.

    Article  PubMed  Google Scholar 

  10. Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: A meta-analysis. J Am Coll Cardiol 2007;49:227-37.

    Article  PubMed  Google Scholar 

  11. Rozanski A, Gransar H, Hayes SW, Friedman JD, Hachamovitch R, Berman DS. Comparison of long-term mortality risk following normal exercise vs adenosine myocardial perfusion SPECT. J Nucl Cardiol 2010;17:999-1008.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Sharma J, Roncari C, Giedd KN, Fox JT, Kanei Y. Patients with adenosine-induced ST-segment depressions and normal myocardial perfusion imaging: Cardiac outcomes at 24 months. J Nucl Cardiol 2010;17:874-80.

    Article  PubMed  Google Scholar 

  13. Supariwala A, Uretsky S, Singh P, Memon S, Khokhar SS, Wever-Pinzon O, et al. Synergistic effect of coronary artery disease risk factors on long-term survival in patients with normal exercise SPECT studies. J Nucl Cardiol 2011;18:207-14.

    Article  PubMed  Google Scholar 

  14. Johnson NP, Schimmel DR Jr, Dyer SP, Leonard SM, Holly TA. Survival by stress modality in patients with a normal myocardial perfusion study. Am J Cardiol 2011;107:986-9.

    Article  PubMed  Google Scholar 

  15. Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al. Appropriate use criteria for cardiac radionuclide imaging. J Am Coll Cardiol 2009;53:2201-29.

    Article  PubMed  Google Scholar 

  16. Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguadé-Bruix S, Olona M, Palet J, et al. Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: Improved diagnostic yield in coronary artery disease. J Am Coll Cardiol 1997;29:531-6.

    Article  CAS  PubMed  Google Scholar 

  17. Castell-Conesa J, Aguadé-Bruix S, García-Burillo A, González JM, Canela MT, Oller G, et al. Reproducibilidad de la gated-SPECT de perfusión miocárdica en la valoración de la función ventricular y su comparación con la ventriculografía isotópica. Rev Esp Cardiol 2004;57:931-8.

    Article  PubMed  Google Scholar 

  18. Schinkel AFL, Boiten HJ, van der Sijde JN, Ruitinga PR, Sijbrands EJG, Valkema R, et al. 15-Year outcome after normal exercise 99mTc-sestamibi myocardial perfusion imaging: What is the duration of low risk after normal scan? J Nucl Cardiol 2012;19:901-6.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Supariwala A, Uretsky S, DePuey EG, Thotakura G, Kanneganti S, Guriginjakunta N, et al. Influence of mode of stress and coronary risk factor burden upon long-term mortality following normal stress myocardial perfusion single-photon emission computed tomographic imaging. Am J Cardiol 2013;111:846-50.

    Article  PubMed  Google Scholar 

  20. Simonsen JA, Gerke O, Rasj CK, Tamadoni M, Thomassen A, Hess S, et al. Prognosis in patients with suspected or known ischemic heart disease and normal myocardial perfusion: Long-term outcome and temporal risk variations. J Nucl Cardiol 2013;20:347-57.

    Article  PubMed  Google Scholar 

  21. Ottenhof MJM, Tjong Joe Wai MCG, Boiten HJ, Korbee RS, Valkema R, van Domburg RT, et al. 12-Year outcome after normal myocardial perfusion SPECT in patients with known coronary artery disease. J Nucl Cardiol 2013;20:748-54.

    Article  PubMed  Google Scholar 

  22. Rozanski A, Gransar H, Min JK, Hayes SW, Friedman JD, Thompson LEJ, et al. Long-term mortality following normal exercise myocardial perfusion SPECT according to coronary disease risk factors. J Nucl Cardiol 2014;21:341-50.

    Article  PubMed  Google Scholar 

  23. Candell-Riera J, Fernández C, Escudero F, de León G, Aguadé-Bruix S, Castell-Conesa J. Prevalencia y significado angiográfico de la SPECT de perfusión miocárdica normal con electrocardiograma de esfuerzo positivo. Rev Esp Cardiol 2004;57:894-7.

    Article  PubMed  Google Scholar 

  24. Carryer DJ, Askew JW, Hodge DO, Miller TD, Gibbons RJ. The timing and impact of follow-up studies after normal stress single-photon emission computed tomography sestamibi studies. Circ Cardiovasc Imaging 2010;3:520-6.

    Article  PubMed  Google Scholar 

  25. Miller TD, Hodge DO, Milavetz JJ, Gibbons RJ. A normal stress SPECT scan is an effective gatekeeper for coronary angiography. J Nucl Cardiol 2007;14:187-93.

    Article  PubMed  Google Scholar 

  26. Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999;100:1035-42.

    Article  CAS  PubMed  Google Scholar 

  27. Dona M, Massi L, Settimo L, Bartolini M, Gianni G, Pupi A, et al. Prognostic implications of post-stress ejection fraction decrease detected by gated SPECT in the absence of stress-induced perfusion abnormalities. Eur J Nucl Med Mol Imaging 2011;38:485-90.

    Article  PubMed  Google Scholar 

  28. Acampa W, Petretta M, Cuocolo R, Daniele S, Cantoni V, Cuocolo A. Warranty period of normal stress myocardial perfusion imaging in diabetic patients: A propensity score analysis. J Nucl Cardiol 2014;21:50-6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Prof. Demos Demosthenous (London) for his grammatical English correction.

Disclosures

None.

Author information

Authors and Affiliations

  1. Cardiology Department, Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Paseo Vall d’Hebron 119-129, 08035, Barcelona, Spain

    Guillermo Romero-Farina MD, PhD, FESC, FASNC, Jaume Candell-Riera MD, PhD, FESC, Ignacio Ferreira-González MD, PhD, Gemma Cuberas-Borrós BSc, Nazarena Pizzi MD & David García-Dorado MD, PhD, FACC, FESC

  2. Department of Nuclear Medicine, Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

    Santiago Aguadé-Bruix MD

Authors
  1. Guillermo Romero-Farina MD, PhD, FESC, FASNC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaume Candell-Riera MD, PhD, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Santiago Aguadé-Bruix MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ignacio Ferreira-González MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gemma Cuberas-Borrós BSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nazarena Pizzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David García-Dorado MD, PhD, FACC, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillermo Romero-Farina MD, PhD, FESC, FASNC.

Additional information

See related editorial, doi: 10.1007/s12350-014-9974-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero-Farina, G., Candell-Riera, J., Aguadé-Bruix, S. et al. Warranty periods for normal myocardial perfusion stress SPECT. J. Nucl. Cardiol. 22, 44–54 (2015). https://doi.org/10.1007/s12350-014-9957-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-014-9957-6

Keywords

Search

Navigation